In Vivo Assessment of the Impact of Efflux Transporter on Oral Drug Absorption Using Portal Vein–Cannulated Rats

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drug Metabolism And Disposition

• Publication date

  2013-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.113.051680PMID 23686319
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP

  2012cited by this paper
• Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

  2012cited by this paper
• Assessment of Intestinal Availability of Various Drugs in the Oral Absorption Process Using Portal Vein-Cannulated Rats

  2012influential reference
• Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout Rats Generated by Zinc Finger Nucleases

  2012cited by this paper
• Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout Mice

  2012cited by this paper
• Pharmacokinetic Modeling to Assess Factors Affecting the Oral Bioavailability of the Lactone and Carboxylate Forms of the Lipophilic Camptothecin Analogue AR-67 in Rats

  2012cited by this paper
• Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics

  2012cited by this paper
• Deletion of Abcg2 Has Differential Effects on Excretion and Pharmacokinetics of Probe Substrates in Rats

  2012cited by this paper
• Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

  2012cited by this paper
• Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.

  2011cited by this paper
• Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.

  2011cited by this paper
• BDDCS Applied to Over 900 Drugs

  2011cited by this paper
• Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

  2010cited by this paper
• P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib

  2009cited by this paper
• An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

  2009influential reference
• N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.

  2009cited by this paper
• Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.

  2009cited by this paper
• Marked impact of P‐glycoprotein on the absorption of TAK‐427 in rats

  2008cited by this paper
• Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells

  2008cited by this paper
• Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3

  2007influential reference
• In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.

  2006cited by this paper
• Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse

  2006cited by this paper
• Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

  2004cited by this paper
• Transport Characteristics of Fexofenadine in the Caco-2 Cell Model

  2004cited by this paper
• Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

  2004cited by this paper
• The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.

  2003cited by this paper
• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

  2003cited by this paper
• Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979

  2003cited by this paper
• Novel Experimental Parameters to Quantify the Modulation of Absorptive and Secretory Transport of Compounds by P-Glycoprotein in Cell Culture Models of Intestinal Epithelium

  2003cited by this paper
• Role Reversal for Anticancer Agents

  2002cited by this paper
• Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

  2002cited by this paper
• Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

  1999cited by this paper
• OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

  1999cited by this paper
• Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

  1999cited by this paper
• Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

  1997cited by this paper
• Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

  1992cited by this paper
• Contribution of the intestine to the first-pass metabolism of felodipine in the rat.

  1989cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.

  1979cited by this paper

• Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1

  2023cites this paper
• Evaluation of the Herb-Drug Interaction (HDI) Potential of Zingiber officinale and Its Major Phytoconstituents.

  2023cites this paper
• Construction of extended and functional bile canaliculi using long-term sandwich-cultured cryopreserved human hepatocytes and the application of hepatocytes for predicting the biliary excretion of pharmaceutical and food-related compounds.

  2023cites this paper
• Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents

  2021cites this paper
• Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

  2021cites this paper
• Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs

  2021cites this paper
• ABC Transporters: An Overview

  2021cites this paper
• Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and in vitro-in vivo correlation of P-glycoprotein inhibition

  2021cites this paper
• The impact of breast cancer resistant protein (BCRP/ABCG2) on drug transport across Caco-2 cell monolayers.

  2020cites this paper
• The Effects of P-glycoprotein Inhibitor Zosuquidar on the Sex and Time-Dependent Pharmacokinetics of Parenterally Administered Talinolol in Mice.

  2020cites this paper
• Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.

  2019cites this paper
• Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats

  2019cites this paper
• Effects of pharmaceutical excipients on the intestinal transport and absorption of breast cancer resistance protein substrates Ph. D. Dissertation

  2019cites this paper
• Impact of P-Glycoprotein on Intestinal Absorption of an Inhibitor of Apoptosis Protein Antagonist in Rats: Mechanisms of Nonlinear Pharmacokinetics and Food Effects

  2018cites this paper
• In Vivo Preclinical Approaches to Deconvolute The Contribution of First-Pass Effect from Oral Absorption

  2017cites this paper
• In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey.

  2017cites this paper
• Clearance Prediction Methodology Needs Fundamental Improvement: Trends Common to Rat and Human Hepatocytes/Microsomes and Implications for Experimental Methodology

  2017cites this paper
• Pharmacokinetics of mangiferin and its metabolite—norathyriol, Part 2: Influence of UGT, CYP450, P‐gp, and enterobacteria and the potential interaction in Rhizoma Anemarrhenae decoction with timosaponin B2 as the major contributor

  2016cites this paper
• Application of a Human Intestinal Epithelial Cell Monolayer to the Prediction of Oral Drug Absorption in Humans as a Superior Alternative to the Caco-2 Cell Monolayer.

  2016cites this paper
• Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models

  2015cites this paper
• Quantitative Assessment of Intestinal First-pass Metabolism of Oral Drugs Using Portal-vein Cannulated Rats

  2015cites this paper
• Dioscin enhances methotrexate absorption by down-regulating MDR1 in vitro and in vivo.

  2014cites this paper